Comprehensive Notes: Signal Transduction Lecture
Student Learning Outcomes
Explain the role of signaling pathways in health and disease.
Compare and contrast G-protein coupled receptor (GPCR) pathways.
Analyze receptor tyrosine kinase (RTK) and downstream transcription factor signaling.
Describe intracellular signaling mechanisms in stress and trauma physiology.
Evaluate cytokine-mediated signaling in inflammation and autoimmunity.
Examine vascular signaling pathways.
Integrate pharmacological interventions with signaling mechanisms.
1. BRAF V600E melanoma and Vemurafenib (Mechanism of action)
Clinical scenario: 42-year-old male with melanoma; biopsy shows BRAF V600E mutation; treated with Vemurafenib.
Correct mechanism: .
Rationale:
BRAF V600E is a constitutively active form of RAF that drives MAPK signaling (RAS–RAF–MEK–ERK).
Vemurafenib is a selective small-molecule inhibitor designed to target the mutant BRAF V600E protein.
Inhibition reduces MAPK pathway signaling and downstream transcriptional programs driving proliferation.
Context and related pathways:
RTK activation can funnel signals via adaptor proteins Grb2 and SOS to activate RAS (a small GTPase). NF-1 negatively regulates this step.
Activated RAS can trigger multiple downstream pathways:
(i) PI3K → AKT → GSK3 (cell survival and metabolism)
(ii) RalGDS → Ral → RBP1 (cytoskeletal dynamics and vesicle trafficking)
(iii) RAF kinases (ARAF, BRAF, CRAF) linking to MAPK cascade
MAPK cascade: RAF kinases phosphorylate MEK, which phosphorylates ERK; Activated ERK translocates to the nucleus and phosphorylates transcription factors (e.g., Ets, Fos, Elk1, MYC) and regulators of cell cycle (Cyclin D), glucose transport (GLUT1), hormone responses (EP-1, ER).
Outcome: gene expression changes promote cell proliferation, differentiation, and survival.
Key statistics:
BRAF mutations occur in roughly of melanomas.
The V600E allele is a common oncogenic driver across several cancers, including melanoma.
Additional notes:
BRAF is an oncogene; when mutated, signaling can become constitutively active.
Targeted therapies like Vemurafenib illustrate precision medicine by inhibiting oncogenic BRAF activity rather than upstream Ras or downstream MEK directly (though in some contexts MEK inhibitors may be used).
Potential caveat: paradoxical activation of wild-type BRAF in non-mutant cells can occur with some BRAF inhibitors, requiring clinical monitoring.
2. NO–cGMP–PKG pathway in vascular signaling; impact of NO bioavailability
Clinical context: 84-year-old woman with atherosclerosis and peripheral arterial disease; decreased NO bioavailability.
Key consequence: A decrease in NO bioavailability leads to a decrease in downstream signaling via the NO–cGMP pathway.
Core signaling axis:
NO synthase (eNOS) from arginine → NO
NO diffuses to adjacent smooth muscle cells and activates soluble guanylyl cyclase (sGC)
sGC converts
cGMP activates Protein Kinase G (PKG)
PKG phosphorylates targets leading to smooth muscle relaxation, platelet inhibition, and changes in gene expression; overall vascular homeostasis and anti-thrombotic balance
In disease (atherosclerosis):
Chronic inflammation, oxidative stress, and endothelial dysfunction reduce NO bioavailability.
Consequence: diminished cGMP production and PKG signaling → reduced vasodilation, vascular stiffness, increased platelet aggregation, and pro-inflammatory/pro-thrombotic shift.
Pathway components and interactions (highlights):
NO synthase (eNOS) and NO donors deliver NO
Guanylyl cyclase (soluble, sGC) uses
cGMP-dependent kinases (PKG) regulate downstream targets, including phosphodiesterases that terminate signaling
NO signaling modulates gene expression via transcription factors linked to cGMP signaling
Visual summary (conceptual):
NO → sGC activation → → vasodilation, anti-platelet, anti-inflammatory effects
Clinical relevance: restoring NO bioavailability or activating the NO–cGMP axis can mitigate endothelial dysfunction and vascular disease progression.
Supporting notes from pathway details:
NO is synthesized from L-arginine by endothelial nitric oxide synthase (eNOS).
NO activates soluble guanylate cyclase to produce .
(vasodilation, anti-platelet, gene regulation).
Inflammation/oxidative stress lower NO bioavailability, shifting vascular signaling toward pro-inflammatory and pro-thrombotic states.
NO donors and pharmacologic modulators (e.g., BAY-58-2667, YC-1) illustrate therapeutic strategies targeting this pathway.
3. Wnt signaling, β-catenin, and hereditary colon cancer; Myc as an oncogenic hub
Clinical scenario: 17-year-old female with thousands of adenomatous polyps; family history of colon cancer; familial cancer risk.
Most likely hereditary mechanism: Consistently active beta-catenin binding DNA (i.e., constitutive Wnt/β-catenin signaling).
Canonical Wnt pathway overview:
OFF state: In the absence of a Wnt ligand, the destruction complex (Axin, APC, CKI, GSK3) phosphorylates β-catenin; β-TrCP ubiquitinates, leading to proteasomal degradation. As a result, β-catenin does not accumulate; transcription factors like TCF are bound to corepressors (TLE/HDAC) and Wnt-responsive genes are repressed.
ON state: Wnt ligand binds Frizzled and LRP5/6; Dishevelled (Dvl) is activated and disrupts the destruction complex. β-Catenin is stabilized, accumulates in the cytosol, translocates to the nucleus, and interacts with TCF to activate transcription of Wnt target genes (proliferation, differentiation, survival).
Myc as an oncogenic hub:
Myc is a central node influenced by multiple signaling pathways (Wnt, Ras, Notch, BRCA1, TGF-β, ER-α, EGFR/Her2).
Deregulated Myc signaling drives hallmarks of cancer: uncontrolled proliferation, transformation, immortalization, EMT, etc.
Within this network, Wnt signaling drives Myc activation via β-catenin/TCF-mediated transcription.
Implications:
Germline or somatic mutations that stabilize β-catenin or disrupt the destruction complex promote colon tumorigenesis.
Therapeutic strategies may target components of Wnt signaling or downstream effectors like Myc.
4. Acromegaly: GH–IGF-1 axis; pituitary adenoma etiology
Clinical vignette: 32-year-old woman with acne, oily skin, hirsutism, elevated testosterone, sweating, acral growth (enlarged hands/feet), irregular menses, galactorrhea; pituitary MRI shows adenoma with cavernous sinus invasion.
Best etiology: Growth hormone secretion is increased due to the pituitary tumor, with elevated IGF-1 causing signs and symptoms of acromegaly.
Pathophysiology:
Normal: GH from anterior pituitary stimulates liver to produce insulin-like growth factor 1 (IGF-1).
IGF-1 mediates growth of bone, soft tissue, and organs and modulates metabolic effects.
In acromegaly, a pituitary adenoma causes excess GH → markedly elevated IGF-1, leading to acral overgrowth, soft tissue changes, menstrual irregularities, galactorrhea, and systemic features.
Supporting notes:
The clinical vignette shows that the primary driver is GH excess from a pituitary tumor; IGF-1 is the mediator of the systemic effects.
The MRI finding of cavernous sinus invasion supports a pituitary adenoma with invasive characteristics.
Other options (genetic mutations, testosterone changes) do not coherently explain the constellation of findings.
Pathophysiology recap:
GH ≔ anterior pituitary hormone; stimulates hepatic IGF-1; IGF-1 promotes growth and metabolic effects.
Excess GH + IGF-1 underlies acromegalic features.
Key figure takeaway (per slides): Pituitary adenoma → increased GH secretion → increased IGF-1 → acromegaly features.
5. α1-adrenergic receptor signaling in pheochromocytoma context
Clinical scenario: 44-year-old man with episodic headaches, palpitations, sweating, severe hypertension; adrenal medulla tumor; overexpression of α1-adrenergic receptors; preoperative phenoxybenzamine (an α-adrenergic blocker) given.
Best explanation for intracellular signaling:
Activation of phospholipase C (PLC) via Gq family signaling; cleavage of PIP₂ into IP₃ and DAG; IP₃ increases intracellular Ca²⁺ release; DAG activates protein kinase C (PKC).
Correct option: d. Activation of phospholipase C, leading to cleavage of PIP₂ into IP₃ and DAG; IP₃ increases intracellular Ca²⁺ release, and DAG activates protein kinase C.
Key signaling pathway details:
α1-adrenergic receptors couple to Gq proteins.
Gq → PLC-β activation → PIP₂ hydrolysis → IP₃ + DAG.
IP₃ mobilizes Ca²⁺ from ER; DAG activates PKC; together elicit vascular smooth muscle contraction and other Ca²⁺-dependent responses.
Contextual notes:
Phenoxybenzamine is used to block α-adrenergic receptors pre-surgery to prevent catecholamine-induced hypertensive crises.
This pathway contrasts with α2-adrenergic receptors and β-adrenergic receptor signaling, which have different G protein couplings and second messengers.
6. Cholera toxin vs Gq signaling: mechanistic differences
Clinical scenario: 29-year-old man with profuse watery diarrhea after travel; cholera toxin exposure; toxin ADP-ribosylates Gsα, locking it in a GTP-bound active state, constitutively activating adenylate cyclase; elevated cAMP.
Question: How does this mechanism differ from Gq-mediated receptor activation?
Correct explanation (answer):
Gq signaling activates phospholipase C (PLC), generating IP₃ and DAG from PIP₂ (leading to Ca²⁺ release and PKC activation).
Gs signaling activates adenylate cyclase to increase cAMP.
Mechanistic summary:
Gq → PLC-β → IP₃ + DAG → Ca²⁺ release + PKC activation (PI pathway).
Gs → Adenylate cyclase → ↑cAMP → PKA activation (cAMP pathway).
Cholera toxin mechanism details:
Cholera toxin binds GM1 ganglioside; endocytosis; retrograde transport to ER; A1 subunit ADP-ribosylates Gsα; Gsα remains GTP-bound active; constitutive activation of adenylyl cyclase → ↑cAMP → PKA → CFTR chloride channel opening → enhanced Cl⁻ secretion and water efflux in the gut.
Clinical consequence: profuse watery diarrhea due to secretory chloride secretion driven by cAMP/PKA pathway.
7. β-Adrenergic signaling, PTSD treatment, and propranolol
Clinical scenario: 24-year-old woman with PTSD symptoms after trauma; treated with propranolol (non-selective β-blocker) to blunt somatic symptoms.
Signaling pathway blocked by propranolol:
Activation of Gs → stimulation of adenylyl cyclase → ↑cAMP → activation of protein kinase A (PKA) pathway (and MAPK) is dampened by β-blockade, reducing downstream signaling.
Correct option: c. Activation of Gs → stimulation of adenylate cyclase → ↑cAMP → activation of protein kinase A
Additional notes on β-adrenergic signaling:
β-adrenergic receptors (β1, β2, β3) are Gs-coupled GPCRs; activation increases cAMP, leading to PKA activation and downstream effects including MAPK pathway engagement and transcriptional regulation (CREB, AP-1, Ets factors).
In acute stress, norepinephrine stimulates β-adrenergic signaling; in chronic stress/PTSD, this pathway contributes to sustained amygdala/hippocampus hyperactivation and impaired fear memory extinction.
Propranolol can blunt physical symptoms and, if given soon after trauma, may influence memory reconsolidation.
Catecholamine-mediated signaling recap (β-adrenergic axis):
Catecholamines (epinephrine, norepinephrine) bind β-adrenergic receptors → Gs activation → adenylyl cyclase activation → transient rise in → activation of PKA and MAPK pathways → activation of transcriptional regulators (CREB, AP-1, Ets) → modulation of inflammation and angiogenesis gene programs.
8. NF-κB signaling in rheumatoid arthritis; canonical and non-canonical pathways
Clinical scenario: 48-year-old woman with chronic joint inflammation; high TNF-α and IL-1β; NF-κB pathway activation in synovial fibroblasts drives inflammation and joint destruction.
Core mechanism: Cytokine signaling activates the IKK complex, leading to phosphorylation and degradation of IκB, freeing NF-κB (p65/p50) to translocate to the nucleus and activate transcription of pro-inflammatory genes.
Canonical pathway (left panel):
Receptors such as TLRs, TNFRs, or IL-1R recruit the IKK complex (IKKα, IKKβ, NEMO).
IKK phosphorylates IκB, marking it for ubiquitin-mediated degradation.
NF-κB dimers (p65/p50) translocate to the nucleus and drive transcription of target genes.
Non-canonical pathway (right panel):
Receptors such as BAFFR, CD40, or RANK stimulate NIK, which phosphorylates IKKα.
Processing of p100 to p52 enables formation of the p52/RELB complex that enters the nucleus to regulate gene expression.
Convergent outcome:
Both canonical and non-canonical NF-κB pathways induce NF-κB–dependent genes encoding cytokines, chemokines, and other mediators that promote inflammation, immune responses, cell survival, proliferation, and apoptosis.
Clinical relevance:
Targeting NF-κB signaling is a key strategy in inflammatory diseases like rheumatoid arthritis due to its central role in driving inflammatory gene programs.
9. RhoA–ROCK signaling and vascular dysfunction in atherosclerosis
Clinical scenario: 62-year-old man with stable angina; endothelial dysfunction; decreased NO bioavailability; increased RhoA/ROCK signaling contributes to vascular pathology.
Mechanism: RhoA in its GTP-bound form activates ROCK, which inhibits myosin light chain phosphatase (MLCP) by phosphorylation of its regulatory subunit (MYPT-1); this leads to increased phosphorylation of myosin light chain (MLC) and enhanced actomyosin contraction. ROCK also phosphorylates LIM kinase (LIMK), which inactivates cofilin and stabilizes F-actin, reinforcing cytoskeletal contractility and organization.
Correct concept: RhoA-GTP activates ROCK → MLCP inhibition → increased MLC phosphorylation → sustained smooth muscle contraction; plus ROCK-driven cytoskeletal changes promote contraction and vascular dysfunction.
Pathophysiological significance:
Heightened RhoA/ROCK activity contributes to vasoconstriction, endothelial dysfunction, and progression of atherosclerotic disease.
Key components and steps (summary):
Stimuli (angiotensin II, endothelin-1, thrombin) activate RhoGEF → RhoA-GTP
RhoA-GTP activates ROCK
ROCK phosphorylates MYPT-1 (MLCP regulatory subunit) → MLCP inhibition
ROCK may also phosphorylate MLC directly
ROCK phosphorylates LIMK → inactivates cofilin → promotes F-actin stabilization
Result: increased actomyosin contractility and vascular tone
Closing takeaway
The lecture emphasizes integration of signaling pathways across RTK and GPCR families, second messengers (cAMP, cGMP, Ca²⁺, IP₃, DAG), transcriptional regulation (NF-κB, CREB, Myc, Ets Family), and pharmacologic interventions that modulate these pathways (e.g., Vemurafenib, propranolol, alpha-blockade, NO donors).
Understanding how mutations (e.g., BRAF V600E, APC/β-catenin axis), hormones (GH/IGF-1), and cytokine signaling shape disease phenotypes helps connect molecular mechanisms to clinical outcomes and therapies.
"Thank you!"